Skip to main content
OpenTrials

Clinical trial condition

Recurrent Melanoma

Explore clinical trials studying Recurrent Melanoma. Study availability and eligibility vary by location and protocol.

83 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Melanoma trial results

Recruiting

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

NCT05136196

Conditions
Carcinoma, Carcinoma, Squamous Cell, Clinical Stage III Cutaneous Melanoma AJCC v8, +52 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
View all 229 locations
View Trial Details
Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma, +14 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 838 locations
View Trial Details
Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

NCT01274338

Conditions
Melanoma, Melanoma of Unknown Primary, Neoplasms, +14 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Providence Hospital Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Regional Hospital Anchorage, Alaska, United States
View all 937 locations
View Trial Details
Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1410 locations
View Trial Details
Active, not recruiting

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT01134614

Conditions
Advanced Melanoma, Melanoma, Metastatic Melanoma, +18 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • VA Palo Alto Health Care System Palo Alto, California, United States
  • Eisenhower Medical Center Rancho Mirage, California, United States
View all 257 locations
View Trial Details
Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT02298959

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +60 more
Locations
  • Moffitt Cancer Center-International Plaza Tampa, Florida, United States
  • Moffitt Cancer Center - McKinley Campus Tampa, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
View Trial Details
Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine Gland Neoplasms, Endocrine System Diseases, +102 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 172 locations
View Trial Details
Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

NCT00937937

Conditions
Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma, +16 more
Locations
  • Providence Hospital Mobile, Alabama, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Highlands Oncology Group - Rogers Rogers, Arkansas, United States
View all 190 locations
View Trial Details
Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details

Related conditions